STOCK TITAN

[S-8] Astera Labs, Inc. Employee Benefit Plan Registration

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-8
Rhea-AI Filing Summary

Astera Labs, Inc. (ALAB) filed a Form S-8 on 18 June 2025 to register 9,721,048 additional shares of common stock for issuance under two employee equity programs:

  • 2024 Stock Option & Incentive Plan: 8,100,874 shares
  • 2024 Employee Stock Purchase Plan: 1,620,174 shares
The filing relies on General Instruction E, incorporating the prior S-8 (File No. 333-278078, 20 Mar 2024). Astera is classified as a non-accelerated filer and an emerging growth company. Key exhibits include the legal opinion (5.1), auditor consent (23.1) and plan documents (99.1, 99.2). By registering these shares, the company preserves capacity to issue equity to employees as outlined in its 10-K (14 Feb 2025), 10-Q (7 May 2025) and recent 8-Ks (3 Mar & 10 Jun 2025), all of which are incorporated by reference.

Astera Labs, Inc. (ALAB) ha presentato un Modulo S-8 il 18 giugno 2025 per registrare 9.721.048 azioni aggiuntive di azioni ordinarie da emettere nell'ambito di due programmi di equity per i dipendenti:

  • Piano di Opzioni Azionarie e Incentivi 2024: 8.100.874 azioni
  • Piano di Acquisto Azionario Dipendenti 2024: 1.620.174 azioni
La presentazione si basa sull'Istruzione Generale E, incorporando il precedente S-8 (Numero di File 333-278078, 20 marzo 2024). Astera è classificata come non-accelerated filer e emerging growth company. Gli allegati principali includono l'opinione legale (5.1), il consenso del revisore (23.1) e i documenti del piano (99.1, 99.2). Registrando queste azioni, la società mantiene la capacità di emettere equity ai dipendenti come indicato nei suoi documenti 10-K (14 febbraio 2025), 10-Q (7 maggio 2025) e negli ultimi 8-K (3 marzo e 10 giugno 2025), tutti incorporati per riferimento.

Astera Labs, Inc. (ALAB) presentó un Formulario S-8 el 18 de junio de 2025 para registrar 9,721,048 acciones adicionales de acciones comunes para su emisión bajo dos programas de acciones para empleados:

  • Plan de Opciones sobre Acciones e Incentivos 2024: 8,100,874 acciones
  • Plan de Compra de Acciones para Empleados 2024: 1,620,174 acciones
La presentación se basa en la Instrucción General E, incorporando el S-8 previo (Número de archivo 333-278078, 20 de marzo de 2024). Astera está clasificada como no acelerada y compañía emergente en crecimiento. Los anexos clave incluyen la opinión legal (5.1), consentimiento del auditor (23.1) y documentos del plan (99.1, 99.2). Al registrar estas acciones, la empresa conserva la capacidad de emitir acciones a los empleados según lo detallado en sus reportes 10-K (14 de febrero de 2025), 10-Q (7 de mayo de 2025) y recientes 8-K (3 de marzo y 10 de junio de 2025), todos incorporados por referencia.

Astera Labs, Inc. (ALAB)는 2025년 6월 18일에 두 가지 직원 주식 프로그램에 따라 발행할 9,721,048주 추가 보통주를 등록하기 위해 Form S-8을 제출했습니다:

  • 2024년 스톡 옵션 및 인센티브 플랜: 8,100,874주
  • 2024년 직원 주식 구매 계획: 1,620,174주
이 제출은 일반 지침 E를 기반으로 하며, 이전 S-8 (파일 번호 333-278078, 2024년 3월 20일)을 포함합니다. Astera는 비가속 제출자이자 신흥 성장 기업으로 분류됩니다. 주요 첨부 문서에는 법률 의견서(5.1), 감사인 동의서(23.1), 플랜 문서(99.1, 99.2)가 포함되어 있습니다. 이 주식을 등록함으로써 회사는 10-K(2025년 2월 14일), 10-Q(2025년 5월 7일), 최근 8-K(2025년 3월 3일 및 6월 10일)에 명시된 대로 직원에게 주식을 발행할 수 있는 권한을 유지합니다. 이 모든 문서는 참조로 포함되어 있습니다.

Astera Labs, Inc. (ALAB) a déposé un Formulaire S-8 le 18 juin 2025 pour enregistrer 9 721 048 actions supplémentaires ordinaires à émettre dans le cadre de deux programmes d'actions pour employés :

  • Plan d'options d'achat d'actions et d'incitations 2024 : 8 100 874 actions
  • Plan d'achat d'actions pour employés 2024 : 1 620 174 actions
Le dépôt s'appuie sur l'Instruction Générale E, incorporant le précédent S-8 (Numéro de dossier 333-278078, 20 mars 2024). Astera est classée comme un déposant non accéléré et une entreprise en croissance émergente. Les pièces jointes clés comprennent l'avis juridique (5.1), le consentement de l'auditeur (23.1) et les documents des plans (99.1, 99.2). En enregistrant ces actions, la société conserve la capacité d'émettre des actions aux employés comme indiqué dans ses rapports 10-K (14 février 2025), 10-Q (7 mai 2025) et récents 8-K (3 mars et 10 juin 2025), tous incorporés par référence.

Astera Labs, Inc. (ALAB) reichte am 18. Juni 2025 ein Formular S-8 ein, um 9.721.048 zusätzliche Stammaktien zur Ausgabe im Rahmen von zwei Mitarbeiterbeteiligungsprogrammen zu registrieren:

  • Aktienoptions- und Anreizplan 2024: 8.100.874 Aktien
  • Mitarbeiteraktienkaufplan 2024: 1.620.174 Aktien
Die Einreichung stützt sich auf Allgemeine Anweisung E und bezieht das vorherige S-8 (Aktenzeichen 333-278078, 20. März 2024) mit ein. Astera wird als nicht beschleunigter Einreicher und aufstrebendes Wachstumsunternehmen eingestuft. Wichtige Anlagen umfassen die Rechtsmeinung (5.1), die Zustimmung des Wirtschaftsprüfers (23.1) sowie die Planunterlagen (99.1, 99.2). Durch die Registrierung dieser Aktien sichert sich das Unternehmen die Möglichkeit, Eigenkapital an Mitarbeiter auszugeben, wie in seinem 10-K-Bericht (14. Februar 2025), 10-Q-Bericht (7. Mai 2025) und den jüngsten 8-K-Berichten (3. März und 10. Juni 2025) beschrieben, die alle durch Verweis einbezogen sind.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine S-8 adds 9.7 M shares to equity plans; administrative, limited immediate market impact.

This registration statement is a standard evergreen increase under Astera Labs’ 2024 equity compensation programs. It neither raises capital nor alters operating fundamentals; it simply registers shares previously authorized by the board for future employee grants and ESPP purchases. The filing references prior corporate governance documents and confirms EGC and non-accelerated filer status. For investors, potential dilution is already contemplated by plan limits disclosed in earlier SEC filings, so the immediate effect is neutral.

Astera Labs, Inc. (ALAB) ha presentato un Modulo S-8 il 18 giugno 2025 per registrare 9.721.048 azioni aggiuntive di azioni ordinarie da emettere nell'ambito di due programmi di equity per i dipendenti:

  • Piano di Opzioni Azionarie e Incentivi 2024: 8.100.874 azioni
  • Piano di Acquisto Azionario Dipendenti 2024: 1.620.174 azioni
La presentazione si basa sull'Istruzione Generale E, incorporando il precedente S-8 (Numero di File 333-278078, 20 marzo 2024). Astera è classificata come non-accelerated filer e emerging growth company. Gli allegati principali includono l'opinione legale (5.1), il consenso del revisore (23.1) e i documenti del piano (99.1, 99.2). Registrando queste azioni, la società mantiene la capacità di emettere equity ai dipendenti come indicato nei suoi documenti 10-K (14 febbraio 2025), 10-Q (7 maggio 2025) e negli ultimi 8-K (3 marzo e 10 giugno 2025), tutti incorporati per riferimento.

Astera Labs, Inc. (ALAB) presentó un Formulario S-8 el 18 de junio de 2025 para registrar 9,721,048 acciones adicionales de acciones comunes para su emisión bajo dos programas de acciones para empleados:

  • Plan de Opciones sobre Acciones e Incentivos 2024: 8,100,874 acciones
  • Plan de Compra de Acciones para Empleados 2024: 1,620,174 acciones
La presentación se basa en la Instrucción General E, incorporando el S-8 previo (Número de archivo 333-278078, 20 de marzo de 2024). Astera está clasificada como no acelerada y compañía emergente en crecimiento. Los anexos clave incluyen la opinión legal (5.1), consentimiento del auditor (23.1) y documentos del plan (99.1, 99.2). Al registrar estas acciones, la empresa conserva la capacidad de emitir acciones a los empleados según lo detallado en sus reportes 10-K (14 de febrero de 2025), 10-Q (7 de mayo de 2025) y recientes 8-K (3 de marzo y 10 de junio de 2025), todos incorporados por referencia.

Astera Labs, Inc. (ALAB)는 2025년 6월 18일에 두 가지 직원 주식 프로그램에 따라 발행할 9,721,048주 추가 보통주를 등록하기 위해 Form S-8을 제출했습니다:

  • 2024년 스톡 옵션 및 인센티브 플랜: 8,100,874주
  • 2024년 직원 주식 구매 계획: 1,620,174주
이 제출은 일반 지침 E를 기반으로 하며, 이전 S-8 (파일 번호 333-278078, 2024년 3월 20일)을 포함합니다. Astera는 비가속 제출자이자 신흥 성장 기업으로 분류됩니다. 주요 첨부 문서에는 법률 의견서(5.1), 감사인 동의서(23.1), 플랜 문서(99.1, 99.2)가 포함되어 있습니다. 이 주식을 등록함으로써 회사는 10-K(2025년 2월 14일), 10-Q(2025년 5월 7일), 최근 8-K(2025년 3월 3일 및 6월 10일)에 명시된 대로 직원에게 주식을 발행할 수 있는 권한을 유지합니다. 이 모든 문서는 참조로 포함되어 있습니다.

Astera Labs, Inc. (ALAB) a déposé un Formulaire S-8 le 18 juin 2025 pour enregistrer 9 721 048 actions supplémentaires ordinaires à émettre dans le cadre de deux programmes d'actions pour employés :

  • Plan d'options d'achat d'actions et d'incitations 2024 : 8 100 874 actions
  • Plan d'achat d'actions pour employés 2024 : 1 620 174 actions
Le dépôt s'appuie sur l'Instruction Générale E, incorporant le précédent S-8 (Numéro de dossier 333-278078, 20 mars 2024). Astera est classée comme un déposant non accéléré et une entreprise en croissance émergente. Les pièces jointes clés comprennent l'avis juridique (5.1), le consentement de l'auditeur (23.1) et les documents des plans (99.1, 99.2). En enregistrant ces actions, la société conserve la capacité d'émettre des actions aux employés comme indiqué dans ses rapports 10-K (14 février 2025), 10-Q (7 mai 2025) et récents 8-K (3 mars et 10 juin 2025), tous incorporés par référence.

Astera Labs, Inc. (ALAB) reichte am 18. Juni 2025 ein Formular S-8 ein, um 9.721.048 zusätzliche Stammaktien zur Ausgabe im Rahmen von zwei Mitarbeiterbeteiligungsprogrammen zu registrieren:

  • Aktienoptions- und Anreizplan 2024: 8.100.874 Aktien
  • Mitarbeiteraktienkaufplan 2024: 1.620.174 Aktien
Die Einreichung stützt sich auf Allgemeine Anweisung E und bezieht das vorherige S-8 (Aktenzeichen 333-278078, 20. März 2024) mit ein. Astera wird als nicht beschleunigter Einreicher und aufstrebendes Wachstumsunternehmen eingestuft. Wichtige Anlagen umfassen die Rechtsmeinung (5.1), die Zustimmung des Wirtschaftsprüfers (23.1) sowie die Planunterlagen (99.1, 99.2). Durch die Registrierung dieser Aktien sichert sich das Unternehmen die Möglichkeit, Eigenkapital an Mitarbeiter auszugeben, wie in seinem 10-K-Bericht (14. Februar 2025), 10-Q-Bericht (7. Mai 2025) und den jüngsten 8-K-Berichten (3. März und 10. Juni 2025) beschrieben, die alle durch Verweis einbezogen sind.


As filed with the U.S. Securities and Exchange Commission on June 18, 2025
Registration No. 333-   
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM S-8 
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933  
 
Astera Labs, Inc.
(Exact name of registrant as specified in its charter)  
 

Delaware 82-3437062
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
2345 North First Street
San Jose, CA
 95131
(Address of Principal Executive Offices) (Zip Code)
2024 Stock Option and Incentive Plan
2024 Employee Stock Purchase Plan
(Full titles of the plans)
Jitendra Mohan
Co-Founder and Chief Executive Officer
Astera Labs, Inc.
2345 North First Street
San Jose, CA 95131
(Name and address of agent for service)
(408) 766-3806 
(Telephone number, including area code, of agent for service)
Copies to:
Bradley C. Weber
Julia R. White
Goodwin Procter LLP
601 Marshall Street
Redwood City, CA 94063
(650) 752-3100
 
Philip T. Mazzara
General Counsel & Secretary
Astera Labs, Inc.
2345 North First Street
San Jose, CA 95131
(408) 766-3806
 
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 



Large accelerated filer  Accelerated filer 
Non-accelerated filer  Smaller reporting company 
  Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 
 




EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed by Astera Labs, Inc. (the “Company”) for the purpose of registering an additional 8,100,874 shares of its common stock, par value $0.0001 per share (“Common Stock”), that have become available for issuance pursuant to the Astera Labs, Inc. 2024 Stock Option and Incentive Plan (“2024 Plan”) and an additional 1,620,174 shares of Common Stock that have become available for issuance pursuant to the Astera Labs, Inc. 2024 Employee Stock Purchase Plan (“2024 ESPP”). These shares are securities of the same class as other securities for which a registration statement on Form S-8 was filed with the U.S. Securities and Exchange Commission (the “Commission”) on March 20, 2024 (Commission File No. 333-278078) (the “Prior Registration Statement”).
This Registration Statement is submitted in accordance with General Instruction E to Form S-8 regarding the Registration of Additional Securities. Pursuant to General Instruction E of Form S-8, the contents of the Prior Registration Statement, to the extent relating to the registration of the Common Stock issuable under the 2024 Plan and the 2024 ESPP, are incorporated herein by reference and made part of this Registration Statement, except as otherwise amended, updated or supplemented herein.



PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3. Incorporation of Documents by Reference.
The following documents filed with the Commission are hereby incorporated by reference in this prospectus:
(a)The Company’s Annual Report on Form 10-K, filed with the Commission on February 14, 2025 (File No. 001-41979).
(b)The Company’s Quarterly Report on Form 10-Q, filed with the Commission on May 7, 2025 (File No. 001-41979).
(c)The Company’s Current Reports on Form 8-K filed with the Commission on March 3, 2025 (File No. 001-41979) and June 10, 2025 (File No. 001-41979).
(d)The description of the Company’s common stock contained in the Company’s Registration Statement on Form 8-A (File No. 001-41979) filed with the Commission on March 15, 2024 under Section 12(b) of the Exchange Act, including any amendments or reports filed for the purpose of updating such description.
All documents subsequently filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this Registration Statement and prior to the filing of a post-effective amendment to the Registration Statement which indicates that all of the shares registered hereunder have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the respective dates of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein, modifies or supersedes such earlier statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.




Item 8. Exhibits.
Incorporated by Reference
Exhibit NumberExhibit TitleFormFile No.Exhibit
Filing
Date
Filed
Herewith
4.1
Amended and Restated Certificate of Incorporation of the Registrant
8-K001-419793.13/28/2024
4.2
Second Amended and Restated Bylaws of the Registrant
8-K001-419793.23/28/2024
4.3
Form of common stock certificate of the Registrant
S-1/A333-2772054.13/8/2024
5.1
Opinion of Goodwin Procter LLP
X
23.1
Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm
X
23.2
Consent of Goodwin Procter LLP (included in Exhibit 5.1)
X
24.1
Power of Attorney (contained on signature page hereto)
X
99.1
2024 Stock Option and Incentive Plan, and forms of award agreements thereunder
10-Q
001-41979
10.25/8/2024
99.2
2024 Employee Stock Purchase Plan
10-Q
001-41979
10.35/8/2024
107
Filing Fee Table
X



SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Santa Clara, California, on June 18, 2025.
ASTERA LABS, INC.
Date: June 18, 2025By:
/s/ Jitendra Mohan
Name:
Jitendra Mohan
Title:
Chief Executive Officer

POWER OF ATTORNEY AND SIGNATURES
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Jitendra Mohan, Michael Tate, and Philip Mazzara, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign the Registration Statement on Form S-8 of Astera Labs, Inc., and any or all amendments (including post-effective amendments), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.

SignatureTitleDate
/s/ Jitendra Mohan
Co-Founder, Chief Executive Officer, and DirectorJune 18, 2025
Jitendra Mohan
(Principal Executive Officer)
/s/ Michael Tate
Chief Financial OfficerJune 18, 2025
Michael Tate
(Principal Financial Officer)
/s/ Manuel Alba
Chair of the BoardJune 18, 2025
Manuel Alba
/s/ Craig Barratt
DirectorJune 18, 2025
Craig Barratt
/s/ Stefan Dyckerhoff
DirectorJune 18, 2025
Stefan Dyckerhoff
/s/ Sanjay Gajendra
Co-Founder, President, Chief Operating Officer, and DirectorJune 18, 2025
Sanjay Gajendra
/s/ Michael HurlstonDirectorJune 18, 2025
Michael Hurlston
/s/ Jack Lazar
DirectorJune 18, 2025
Jack Lazar
/s/ Bethany MayerDirectorJune 18, 2025
Bethany Mayer

FAQ

How many new shares is Astera Labs (ALAB) registering on this Form S-8?

9,721,048 shares of common stock (8,100,874 for the 2024 Stock Plan and 1,620,174 for the 2024 ESPP).

Which employee benefit plans are covered by the new registration?

The filing covers the 2024 Stock Option & Incentive Plan and the 2024 Employee Stock Purchase Plan.

What filer status does Astera Labs claim in the S-8?

Astera Labs is a non-accelerated filer and an emerging growth company.

Does the Form S-8 raise cash for Astera Labs?

No. A Form S-8 registers shares for employee compensation; it does not, by itself, generate cash proceeds.

Which previous filings are incorporated by reference in this S-8?

The company’s 2024 10-K, Q1-25 10-Q, and 8-Ks filed 3 Mar 25 and 10 Jun 25 are incorporated.
ASTERA LABS INC

NASDAQ:ALAB

ALAB Rankings

ALAB Latest News

ALAB Latest SEC Filings

ALAB Stock Data

14.17B
142.64M
15.86%
69.18%
5.89%
Semiconductors
Semiconductors & Related Devices
Link
United States
SANTA CLARA